Reported Reactions

Adverse event reports that FDA received

  • Search
  • Watch list

Gait inability adverse event reports that record this term

Kind of term
MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on . The data have the reports that FDA received through .

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on .

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From November 2004 to June 2026, FDA received 32,665 adverse event reports that record the MedDRA preferred term Gait inability. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 3,106 reports in the 12 months to June 2026 and 3,497 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 243 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 3,106 (0.2%) record this term. Reports for female patients were 62.8% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 138 drug pages with 250 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Drugs that the reports with the term Gait inability name as a suspect product, in order of name
DrugClassReports with this term
Acetaminophen1,480
Acetaminophen and codeineOpioid agonist443
Acetaminophen Oxycodone Hydrochloride654
ActemraInterleukin-6 receptor antagonist2,260
AdalimumabTumor necrosis factor blocker1,629
Aimovig826
Alendronate sodiumBisphosphonate1,174
Alendronate Sodium Cholecalciferol375
Alendronic Acid1,107
AmpyraPotassium channel blocker492
ApremilastPhosphodiesterase 4 inhibitor693
AravaAntirheumatic agent1,634
AtomoxetineNorepinephrine reuptake inhibitor262
Atomoxetine hydrochlorideNorepinephrine reuptake inhibitor317
AvonexInterferon beta315
AzathioprinePurine antimetabolite605
Berinert507
Botulinum toxin type aAcetylcholine release inhibitor516
ButransPartial opioid agonist399
Calcium366
Calcium Ascorbate386
Calcium carbonateBlood coagulation factor864
Calcium Glubionate824
CandesartanAngiotensin 2 receptor blocker713
Carbidopa levodopaAromatic amino acid305
CelebrexNonsteroidal anti-inflammatory drug908
CelecoxibNonsteroidal anti-inflammatory drug762
Certolizumab pegolTumor necrosis factor blocker873
CetirizineHistamine-1 receptor antagonist848
Cetirizine hydrochlorideHistamine-1 receptor antagonist1,267
Cetirizine hydrochloride, pseudoephedrine hydrochlorideHistamine-1 receptor antagonist1,079
Chloraprep463
Chlorhexidine630
Chlorhexidine gluconate697
Chlorhexidine Gluconate Isopropyl Alcohol348
Cholecalciferol634
CimziaTumor necrosis factor blocker1,744
CortisoneCorticosteroid690
Cortisone acetateCorticosteroid1,254
CosentyxInterleukin-17A antagonist2,472
DesoximetasoneCorticosteroid1,585
DiclofenacNonsteroidal anti-inflammatory drug1,273
Diclofenac diethylamine751
Diclofenac potassiumNonsteroidal anti-inflammatory drug965
Diclofenac sodiumNonsteroidal anti-inflammatory drug1,827
Dietary Supplement Herbals447
Domperidone maleate346
DoxycyclineTetracycline-class drug283
Doxycycline hyclateTetracycline-class drug369
DupixentInterleukin-4 receptor alpha antagonist421
EnbrelTumor necrosis factor blocker2,920
EntrestoAngiotensin 2 receptor blocker353
EntyvioIntegrin receptor antagonist348
Erelzi1,709
ErgocalciferolProvitamin D2 compound777
EtanerceptTumor necrosis factor blocker378
Flumethasone254
Flumethasone Pivalate1,121
Folic acid1,716
FosamaxBisphosphonate1,393
GilenyaSphingosine 1-phosphate receptor modulator293
GoldStandardized chemical allergen366
Gold Sodium Thiomalate648
GolimumabTumor necrosis factor blocker691
Humira3,650
HydrocortisoneCorticosteroid938
Hydrocortisone acetateCorticosteroid504
HydroxychloroquineAntimalarial1,503
Hydroxychloroquine sulfateAntimalarial1,275
HyrimozTumor necrosis factor blocker439
InfliximabTumor necrosis factor blocker1,536
Isopropyl alcoholStandardized chemical allergen690
KesimptaCD20-directed cytolytic antibody272
KevzaraInterleukin-6 receptor antagonist934
LamictalAnti-epileptic agent378
LamotrigineAnti-epileptic agent253
LeflunomideAntirheumatic agent1,938
Lyrica939
MetforminBiguanide325
MethotrexateFolate analog metabolic inhibitor2,583
Methotrexate sodiumFolate analog metabolic inhibitor482
MethylprednisoloneCorticosteroid480
Methylprednisolone sodium succinateCorticosteroid541
MinocyclineTetracycline-class drug370
Minocycline hydrochlorideTetracycline-class drug307
Mycophenolate mofetilAntimetabolite immunosuppressant884
Myochrysine328
Myrbetriqbeta3-Adrenergic agonist447
NaproxenNonsteroidal anti-inflammatory drug888
Naproxen sodiumNonsteroidal anti-inflammatory drug998
NucalaInterleukin-5 antagonist583
NuplazidAtypical antipsychotic532
OcrevusCD20-directed cytolytic antibody305
OrenciaSelective T cell costimulation modulator2,089
OtezlaPhosphodiesterase 4 inhibitor1,073
OxycodoneOpioid agonist1,331
Oxycodone hydrochlorideOpioid agonist792
Oxycodone Terephthalate976
PantoprazoleProton pump inhibitor536
Pantoprazole sodiumProton pump inhibitor344
Pantoprazole Sodium Anhydrous347
Periogard858
Phenylephrine hydrochloridealpha-1 adrenergic agonist583
Phthalylsulfathiazole1,408
PlaquenilAntimalarial709
PrednisoneCorticosteroid1,958
Pregabalin401
Pseudoephedrine670
Pseudoephedrine hydrochloridealpha-Adrenergic agonist1,020
Quetiapine fumarateAtypical antipsychotic375
RamiprilAngiotensin converting enzyme inhibitor772
RanitidineHistamine-2 receptor antagonist262
RemicadeTumor necrosis factor blocker1,492
RevlimidThalidomide analog367
RinvoqJanus kinase inhibitor596
RituxanCD20-directed cytolytic antibody296
RituximabCD20-directed cytolytic antibody2,248
SimponiTumor necrosis factor blocker1,630
Sirukumab401
SkyriziInterleukin-23 antagonist307
StelaraInterleukin-12 antagonist1,246
Sulfamethoxazole698
Sulfamethoxazole and trimethoprimDihydrofolate reductase inhibitor antibacterial309
Sulfamethoxazole, trimethoprimDihydrofolate reductase inhibitor antibacterial550
SulfasalazineAminosalicylate1,909
Tecfidera542
TocilizumabInterleukin-6 receptor antagonist736
TofacitinibJanus kinase inhibitor419
Tofacitinib citrateJanus kinase inhibitor567
TopicortCorticosteroid274
Topiramate597
Tramadol hydrochlorideOpioid agonist879
Triamcinolone acetonideCorticosteroid612
TumsBlood coagulation factor264
TysabriIntegrin receptor antagonist474
UstekinumabInterleukin-12 antagonist481
Vitamin cVitamin C781
XeljanzJanus kinase inhibitor2,289

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 60 pharmacologic classes with 250 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Pharmacologic classes of the drugs that the reports with the term Gait inability name, in order of name
ClassReports with this term
Acetylcholine release inhibitor620
alpha-1 adrenergic agonist591
alpha-Adrenergic agonist1,020
Aminoglycoside antibacterial256
Aminosalicylate2,108
Angiotensin 2 receptor blocker1,421
Angiotensin converting enzyme inhibitor899
Anti-epileptic agent966
Anti-IgE251
Antimalarial3,487
Antimetabolite immunosuppressant910
Antirheumatic agent3,572
Aromatic amino acid671
Atypical antipsychotic1,603
Benzodiazepine260
beta3-Adrenergic agonist480
Biguanide514
Bisphosphonate2,832
Blood coagulation factor1,405
Calcium channel blocker266
Calculi dissolution agent262
CD20-directed cytolytic antibody3,220
Corticosteroid10,530
Dihydrofolate reductase inhibitor antibacterial941
Factor Xa inhibitor313
Fluoroquinolone antibacterial560
Folate analog metabolic inhibitor3,073
GLP-1 receptor agonist287
Histamine-1 receptor antagonist3,529
Histamine-2 receptor antagonist460
HMG-CoA reductase inhibitor479
Insulin analog612
Integrin receptor antagonist923
Interferon beta536
Interleukin-12 antagonist1,727
Interleukin-17A antagonist2,710
Interleukin-23 antagonist330
Interleukin-4 receptor alpha antagonist464
Interleukin-5 antagonist709
Interleukin-6 receptor antagonist4,100
Janus kinase inhibitor4,006
Kinase inhibitor1,822
Nonsteroidal anti-inflammatory drug8,092
Norepinephrine reuptake inhibitor599
Opioid agonist4,857
Partial opioid agonist636
Phosphodiesterase 4 inhibitor1,768
Potassium channel blocker638
Programmed death Receptor-1 blocking antibody330
Proton pump inhibitor1,133
Provitamin D2 compound798
Purine antimetabolite926
Selective T cell costimulation modulator2,318
Sphingosine 1-phosphate receptor modulator394
Standardized chemical allergen1,227
Substance P/Neurokinin-1 receptor antagonist285
Tetracycline-class drug1,329
Thalidomide analog542
Tumor necrosis factor blocker13,474
Vitamin C963

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Gait inability, by month, five years to June 2026
05001,00020222023202420252026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Gait inability
AgeReportsShareShare as a bar
Under 2380.1%
2 to 112730.8%
12 to 172260.7%
18 to 444,44013.6%
45 to 646,76920.7%
65 to 745,00315.3%
75 and over4,05412.4%
Age not given11,86236.3%
Sex of the patient in the reports that record Gait inability
SexReportsShareShare as a bar
Female20,52862.8%
Male9,61629.4%
Unknown or not given2,5217.7%

Age and sex are as the report gives them. 58.1% of these reports give the United States as the country.

Terms near this one

Official pages

The site checked these addresses on . The links open in a new tab.

Cite this page

Embed this card on your site

Copy this code into your page. The card shows the figures above with their source. A line under the card links to this page.

How embedding works. It is free. Keep the link in the card and the link line under it.

Reported Reactions. Gait inability: adverse event reports that record this term. https://reportedreactions.com/reaction/gait-inability/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of . Reports received through .

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Gait inability mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.

Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on .